SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection
Posted inDiabetes & Endocrinology Neurology news

SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection

A 20‑year TriNetX analysis of 913,428 T2DM patients found SGLT2 inhibitor use associated with a 28% lower Parkinson’s disease risk versus metformin (aHR 0.72), suggesting possible superior neuroprotection and prompting need for prospective confirmation.
Circulating Nanoparticles and Carotenoids as Biomarkers of Rehabilitation Recovery in Parkinson’s Disease
Posted inFamily Medicine & Nutrition Neurology news Specialties

Circulating Nanoparticles and Carotenoids as Biomarkers of Rehabilitation Recovery in Parkinson’s Disease

Intensive treadmill rehabilitation in Parkinson's disease alters the biochemical composition of circulating extracellular vesicle-like particles, particularly increasing carotenoid content, which correlates with improved gait parameters, highlighting a potential biomarker for monitoring rehabilitation efficacy.
Medium‑Chain Triglyceride–Supplemented Ketogenic Diet in Parkinson’s Disease: A Small Randomized Feasibility Trial and What It Means for Clinical Practice
Posted inClinical Updates Family Medicine & Nutrition Neurology news Specialties

Medium‑Chain Triglyceride–Supplemented Ketogenic Diet in Parkinson’s Disease: A Small Randomized Feasibility Trial and What It Means for Clinical Practice

A randomized, double‑blind pilot tested an MCT‑supplemented ketogenic diet (MCT‑KD) in 16 people with moderate Parkinson’s disease. The diet was feasible and acceptable, induced nutritional ketosis by day 4, produced metabolic benefits and nonmotor symptom improvement, but did not change a primary mobility endpoint (TUG) over three weeks.